Profile
ADMP ZTS TAK HLN TEVA NBIX
Company Name Adamis Pharmaceuticals Corporation Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $7.25M $75.04B $41.18B $41.06B $23.19B $14.48B
Employees 0.01K 14.10K 49.28K 25.41K 37.00K 1.70K
CEO Dr. Ebrahim Versi M.D., Ph.D. Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Mr. Kyle W. Gano Ph.D.
Ratings
ADMP ZTS TAK HLN TEVA NBIX
Quant Rating Score 3 3 3 3 1 3
Quant Rating Neutral Neutral Neutral Neutral Strong Sell Neutral
Trading
ADMP ZTS TAK HLN TEVA NBIX
Last Close $0.775 $166.32 $12.99 $9.1 $20.44 $143.03
High 52 $0.78 $199.94 $15.08 $10.69 $22.77 $153.15
Low 52 $0.78 $145.54 $12.6 $8.01 $10.99 $111.62
Price vs. 52 Week High -0.64 % -16.82 % -13.86 % -14.87 % -10.23 % -6.61 %
Price vs. 52 Week Low -0.64 % 14.28 % 3.1 % 13.61 % 85.99 % 28.14 %
Total Return
ADMP ZTS TAK HLN TEVA NBIX
1 Month Return 0 % -6.66 % -3.2 % -6.76 % 23.88 % 12.89 %
3 Month Return 0 % -13.67 % -9.41 % -9.9 % 18.56 % 22.84 %
6 Month Return 0 % -7.1 % -3.35 % 2.25 % 18.29 % -2.98 %
9 Month Return 0 % 10.89 % -2.84 % 13.61 % 53.68 % 6.22 %
YTD Return 0 % 2.08 % -1.89 % -4.61 % -7.26 % 4.78 %
1 Year Return 0 % -16.4 % -13.63 % 5.32 % 80.57 % 8.33 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ADMP ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.04 % 4.66 % 1.68 % - -
Dividend Paid and Capex Coverage Ration (TTM) - 2.1 % 1.34 % - 3.8 % 13.12 %
Dividend Per Share (TTM) - 1.73 % 192 % 0.06 % - -
Payout Ratio (TTM) - 31.44 % 101.62 % - - -
Growth
ADMP ZTS TAK HLN TEVA NBIX
Asset Growth -71.46 % -4.28 % 8.25 % -2.18 % -1.2 % 37.27 %
Gross Profit Growth 69.31 % 3.7 % 1.76 % 5.84 % 9.65 % 26.06 %
Revenue Growth 115.34 % 5.74 % 5.87 % 4.09 % 6.17 % 26.76 %
Revenue 3 Year -92.36 % 31.98 % 33.13 % 13.9 % -6.91 % 71.93 %
Revenue 5 Year -93.12 % 53.64 % 103.83 % 32.87 % -23.33 % 308.36 %
Revenue 10 Year - 103.1 % 152.69 % 32.87 % -40.82 % 44100.16 %
EBIT Growth 21.86 % 6.27 % -56.36 % 9.37 % -84.52 % 0.76 %
Net Income Growth 24.28 % 10.88 % -54.56 % -1.04 % 76.24 % 61.62 %
Net Income 3 Yeari Growth Per Share 68.22 % 47.55 % -61.74 % -8.67 % 86.29 % -41.58 %
Net Income 5 Yeari Growth Per Share 80.59 % 71.94 % 32.36 % 59.66 % 76.28 % 1054.95 %
Net Income 10 Yeari Growth Per Share 85.76 % 404.24 % 35.42 % 59.66 % -133.42 % 470.4 %
Operating Income Growth 21.86 % 6.27 % -56.36 % 9.37 % -84.52 % 0.76 %
Operating Cash Flow Growth (CFG) 31.45 % 23.06 % -26.69 % 1.79 % -13.96 % 14.88 %
Operating 3 Year CFG 53.7 % 14.12 % -29.25 % 48.8 % 10.09 % 62.6 %
Operating 5 Year CFG 67.62 % 37.69 % 118.64 % 166.36 % -48.98 % 275.6 %
Operating 10 Year CFG 60.43 % 274.61 % 384.17 % 166.36 % -67.94 % 1000.37 %
EPS Growth 27.14 % 12.64 % -54.92 % - 76.42 % 59.01 %
EPS Diluted Growth 27.14 % 12.92 % -54.86 % - 76.42 % 58.33 %
Book Value Per Share -103 % 15.25 % 13.54 % 1.35 % -7.25 % 28.15 %
Share Holder 3 Year Equity Growth Per Share -100.8 % 36.7 % 40.38 % -36.6 % -26.74 % 88.86 %
Share Holder 5 Year Equity Growth Per Share -100.39 % 139.55 % 41.33 % -39.41 % -53.44 % 353.33 %
Share Holder 10 Year Equity Growth Per Share 99.27 % 476.36 % 195.14 % -39.41 % -74.76 % 1167.34 %
Dividend Per Share Growth - 15.15 % 1.95 % -85.58 % - -
Dividend 3 Year Growth Per Share - 87.76 % 1.19 % -83.69 % - -
Dividend 5 Year Growth Per Share - 198.29 % 101.42 % -66.42 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % 102.58 % -66.42 % -100 % -
Debt Growth -50.53 % -16.5 % 10.53 % -9.43 % -6.53 % 62.95 %
Free Cash Flow Growth 31.86 % 22.25 % -31.4 % 1.67 % -19.19 % 11.99 %
Updated On 31 Dec 2022 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
ADMP ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 96.02 % 68.87 % 55.23 % 60.68 % 49.84 % 98 %
Return on Assets TTM -0.09 % 16.93 % 1.99 % 3.26 % -2.38 % 10.92 %
Return on Equity TTM 0.33 % 47.99 % 4.04 % 6.54 % -14.6 % 15.68 %
Return on Capital Employed TTM 0.32 % 26.36 % 4.18 % 7.22 % 1.6 % 18.91 %
Net Income Per EBT TTM 123.6 % 79.65 % 108.74 % 65.38 % 176.38 % 73.98 %
EBT Per Ebit TTM 45.68 % 91.46 % 52.35 % 82.95 % -125.67 % 88.81 %
EBIT Per Revenue TTM -160.65 % 36.45 % 11.21 % 17.82 % 2.67 % 26.19 %
Cash Flow To Debt Ratio TTM -4.06 % 43.6 % 16.58 % - 9.78 % -
Receivables Turnover TTM - 6.49 6.3 5.27 4.84 4.66
Payables Turnover TTM - 7.05 4.92 1.23 3.55 0.47
Inventory Turnover TTM - 1.18 1.69 3.03 2.12 0.98
Fixed Asset Turnover TTM 0.84 % 259.93 % 240.84 % 604.62 % 277.85 % 664.93 %
Asset Turnover TTM 0.1 % 63.75 % 31.2 % 33.71 % 40.16 % 63.45 %
Operating Cash Flow Per Share TTM -0.36 6.5 528.88 - 1.64 4.71
Free Cash Flow Per Share TTM -0.36 5.1 321.24 - 1.21 4.35
Cash Per Share TTM 94314.03 % 378.45 % 57241.03 % 5.72 % 292.94 % 1214.64 %
Operating Cash Flow Sales Ratio TTM -28.32 % 32.18 % 18.42 % - 11.07 % 21.24 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 78.37 % 60.74 % - 73.71 % 92.38 %
Cash Flow Coverage Ratios TTM -4.06 % 43.6 % 16.58 % - 9.78 % -
Price To Free Cash Flows Ratio TTM -2.82 32.51 12.84 - 17.17 32.9
Price To Operating Cash Flows Ratio TTM -2.13 25.58 7.79 - 12.64 30.35
Price Cash Flow Ratio TTM -2.13 25.58 7.79 - 12.64 30.35
Income Statement (TTM)
ADMP ZTS TAK HLN TEVA NBIX
Revenue $0B $8.54B $4263.76B $11.3B $15.85B $1.89B
Gross Profit $-0B $5.83B $2832.26B $6.96B $7.65B $1.85B
Gross Profit Ratio -30.1% 68.28% 66.43% 61.59% 48.25% 97.9%
EBITDA $-0.02B $3.69B $874.6B $2.35B $1.57B $0.36B
Net Income $-0.03B $2.34B $144.07B $1.05B $-0.56B $0.25B
EPS Diluted -12.24 5.07 91.16 0.11 -0.5 2.47
Balance Sheet (MRQ)
ADMP ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $6.75B $5029.93B $8.8B $18.48B $0.26B
Total Liabilities $0.01B $9.3B $7834.79B $17.33B $35.35B $1.02B
Total Equity $-0B $4.99B $7274.01B $16.73B $8.13B $2.23B
Total Investments $0B $0.02B $445.7B $0.07B $0.01B $1.63B
Total Debt $0B $6.76B $4843.75B $9.46B $20.15B $0.43B
Total Assets $0.01B $14.29B $15108.79B $34.06B $43.48B $3.25B
Cash Flow Statement (TTM)
ADMP ZTS TAK HLN TEVA NBIX
Net Income $-0.03B $2.34B $144.07B $1.11B $-0.62B $0.25B
Inventory $-0B $-0.36B $-115.74B $-0.13B $0B $0.01B
Dividends Paid $0B $-0.69B $-287.19B $-0.39B $0B $0B
Operating Cash Flow $-0.03B $2.35B $716.34B $2.1B $1.37B $0.39B
Capital Expenditure $-0B $-0.73B $-480.73B $-0.34B $-0.53B $-0.03B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 3.97
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.62
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 13.39
ALVOW Alvotech 3.3
AMPH Amphastar Pharmaceuticals, Inc. 37.38
AMRX Amneal Pharmaceuticals, Inc. 7.72
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 54.43
AQST Aquestive Therapeutics, Inc. 3.09
ASRT Assertio Holdings, Inc. 0.801
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 7.9725
AYTU Aytu BioPharma, Inc. 1.6308
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to ADMP
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 288.253
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 128.027
Unlock